Bimal Shah

Director/Board Member at ANEBULO PHARMACEUTICALS, INC.

48 year

Health Technology

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Rajesh Shrotriya	M	79	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	24 years
Joseph Lawler	M	52	ANEBULO PHARMACEUTICALS, INC.	4 years
Abraham Noah Oler	M	48	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	14 years
Luigi Lenaz	M	83	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	14 years
Daniel George	M	54	ANEBULO PHARMACEUTICALS, INC.	1 years
Nora Brennan	F	55	SPECTRUM PHARMACEUTICALS, INC.	4 years
Jeffrey R. Latts	M	76	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	17 years
Karah Parschauer	F	46	ANEBULO PHARMACEUTICALS, INC.	3 years
Areta Kupchyk	F	67	ANEBULO PHARMACEUTICALS, INC.	3 years
Aron English	M	41	ANEBULO PHARMACEUTICALS, INC.	4 years
Keith M. McGahan	M	-	SPECTRUM PHARMACEUTICALS, INC.	8 years
Scott Anderson	M	-	ANEBULO PHARMACEUTICALS, INC.	2 years
Nathaniel Calloway	M	42	ANEBULO PHARMACEUTICALS, INC.	2 years
Richard Cunningham	M	54	ANEBULO PHARMACEUTICALS, INC.	1 years
James E. Shields	M	72	SPECTRUM PHARMACEUTICALS, INC. Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	14 years
Kenneth Lin	M	51	ANEBULO PHARMACEUTICALS, INC.	3 years
Jason Aryeh	M	55	ANEBULO PHARMACEUTICALS, INC.	3 years
Madison Damour	F	-	ANEBULO PHARMACEUTICALS, INC.	-
Michael A. Grabow	M	-	SPECTRUM PHARMACEUTICALS, INC.	11 years
Michael E. Schick	M	57	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	15 years
Kenneth Cundy	M	65	ANEBULO PHARMACEUTICALS, INC.	2 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Joseph W. Turgeon	M	66	SPECTRUM PHARMACEUTICALS, INC.	9 years
Thomas Riga	M	48	SPECTRUM PHARMACEUTICALS, INC.	10 years
Paul Berns	M	57	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	6 years
Kurt Gustafson	M	56	SPECTRUM PHARMACEUTICALS, INC.	9 years
Elly Ryu	F	43	SPECTRUM PHARMACEUTICALS, INC.	10 years
Brett Scott	M	73	SPECTRUM PHARMACEUTICALS, INC.	-
Dolatrai Vyas	M	80	SPECTRUM PHARMACEUTICALS, INC.	9 years
Krishan K. Arora	M	83	SPECTRUM PHARMACEUTICALS, INC.	3 years
William Ashton	M	73	SPECTRUM PHARMACEUTICALS, INC.	5 years
Cecilia Gonzalo	F	49	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	1 years
Simon Allen	M	56	ANEBULO PHARMACEUTICALS, INC.	1 years
Jeffrey Vacirca	M	55	SPECTRUM PHARMACEUTICALS, INC.	5 years
Anthony Maida	M	59	SPECTRUM PHARMACEUTICALS, INC.	16 years
Elizabeth Czerepak	F	58	SPECTRUM PHARMACEUTICALS, INC.	1 years
Robert Fralin	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Bernice Welles	M	71	SPECTRUM PHARMACEUTICALS, INC.	-
Gilles Gagnon	M	70	SPECTRUM PHARMACEUTICALS, INC.	-
Marc H. Graboyes	M	54	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	8 years
Raymond Cohen	M	65	SPECTRUM PHARMACEUTICALS, INC.	7 years
David Stout	M	70	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	3 years
Anton G. Gueth	M	67	SPECTRUM PHARMACEUTICALS, INC.	1 years
Jonathan Leff	M	55	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	7 years
Ricardo J. Gonzalez	M	53	SPECTRUM PHARMACEUTICALS, INC.	6 years
David Clark	M	56	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	8 years
Leonard M. Greenstein	M	48	SPECTRUM PHARMACEUTICALS, INC.	7 years
Antonis Koutsoukos	M	-	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	6 years
Francois Lebel	M	72	SPECTRUM PHARMACEUTICALS, INC.	4 years
Jennifer Carver	F	70	SPECTRUM PHARMACEUTICALS, INC.	2 years
Stephanie Vigue	F	-	SPECTRUM PHARMACEUTICALS, INC.	3 years
Dennis Kim	M	55	SPECTRUM PHARMACEUTICALS, INC.	1 years
Lyndah K. Dreiling	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Lisa A. Croissant	F	-	SPECTRUM PHARMACEUTICALS, INC.	-
Al DeJesus	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Dilip J. Mehta	M	91	SPECTRUM PHARMACEUTICALS, INC.	2 years
Pramod Gupta	M	63	SPECTRUM PHARMACEUTICALS, INC.	7 years
Brian Holzer	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Nozar Azarnia	M	-	SPECTRUM PHARMACEUTICALS, INC.	-
Steven Fruchtman	M	73	SPECTRUM PHARMACEUTICALS, INC.	2 years
Bruce Goldsmith	M	58	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	4 years
Charles Q. Morris	M	59	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	2 years
George Uy	M	67	SPECTRUM PHARMACEUTICALS, INC.	4 years
Bruce K. Bennett	M	73	Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	4 years
Seth Fischer	M	68	SPECTRUM PHARMACEUTICALS, INC.	3 years
George Tidmarsh	M	64	SPECTRUM PHARMACEUTICALS, INC.	1 years
Michael A. Adam	M	66	SPECTRUM PHARMACEUTICALS, INC.	2 years
Kenneth Joseph Keller	M	61	SPECTRUM PHARMACEUTICALS, INC.	2 years
Lee F. Allen	M	72	SPECTRUM PHARMACEUTICALS, INC.	3 years
Luke Seikkula	M	60	SPECTRUM PHARMACEUTICALS, INC.	3 years
Denny Chu	M	-	SPECTRUM PHARMACEUTICALS, INC.	6 years

Statistics

Country	Connections	% of total
United States	70	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections